STOCKHOLM, April 28, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2026.

First Quarter 2026

Total revenue increased 24 per cent at CER (constant exchange rates), 11 per cent at actual rates, to SEK 7,184 M (6,465)
Haematology revenue increased 24 per cent at CER to SEK 5,186 M (4,632), mainly driven by strong sales of Altuvoct of SEK 1,240 M (455) and of Doptelet of SEK 1,433 M (1,129)
Immunology revenue increased 24 per cent at CER to SEK 1,643 M (1,526), driven by strong sales of Gamifant of SEK 734 M (582) and Kineret of SEK 779 M (735)
Revenue from the strategic portfolio¹ grew by 55 per cent at CER to SEK 4,524 M (3,255)
The adjusted EBITA margin^1,2 was 38 per cent (36), excluding IAC² of SEK 139 M. EBITA¹ was SEK 2,612 M (2,260), corresponding to a margin of 36 per cent (35). EBIT was SEK 1,868 M (1,358)
Earnings per share (EPS) before dilution was SEK 3.81 (2.55) and EPS after dilution was SEK 3.77 (2.52). Adjusted EPS before dilution¹ was SEK 4.11 (2.75) and adjusted EPS after dilution¹ was SEK 4.07 (2.72)
Cash flow from operating activities was SEK 1,126 M (2,295)
The acquisition of Arthrosi Therapeutics, Inc. (Arthrosi) was completed

Outlook 2026 - unchanged

Revenue is anticipated to grow at low double-digit percentage at CER
The adjusted EBITA margin is anticipated to be in the mid 30s percentage of revenue


 1. Alternative Performance Measures (APMs). The definition for IAC was updated during the quarter.



 2. Items affecting comparability (IAC).

Investors, analysts, and the media are invited to a conference call on the same day at 12:30 CEST, 11:30 BST, and 06:30 EDT. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is required to be made public by Sobi pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out below on 28 April 2026 at 08:00 CEST.

Gerard Tobin

Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q1-2026-report--strong-execution-and-pipeline-momentum,c4340868

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4340868/4061124.pdf Q1 2026 Quarterly
                                                          Report

View original content:https://www.prnewswire.co.uk/news-releases/sobi-q1-2026-report-strong-execution-and-pipeline-momentum-302755298.html

Tags

More Like This

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

Sobi Q3 2025 report: Accelerated growth and portfolio momentum